Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
– Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts…